Chlorproguanil/dapsone
Combination of | |
---|---|
Chlorproguanil | Antimalarial drug |
Dapsone | Antibiotic |
Legal status | |
Legal status |
|
Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone,[1] which act synergystically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.[2]
References
- ↑ Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". Lancet Infect Dis. 3 (3): 162–8. PMID 12614733. doi:10.1016/S1473-3099(03)00547-4.
- ↑ Luzzatto, L. (2010). "The rise and fall of the antimalarial Lapdap: A lesson in pharmacogenetics". The Lancet. 376 (9742): 739–741. PMID 20599264. doi:10.1016/S0140-6736(10)60396-0.
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.